Allogeneic hematopoietic stem cells from sources other than bone marrow: Biological and technical aspects

Haematologica

Volumn 82, Issue 2, 1997, Pages 220-238

  Bertolini, Francesco ^b   De Vincentiis, Armando ^b   Lanata, Luigi ^b   Lemoli, Roberto M ^b   Maccario, Rita ^b   Majolino, Ignazio ^b   Ponchio, Luisa ^b   Rondelli, Damiano ^b   Tabilio, Antonio ^b   Zanon, Paola ^b   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Allogeneic transplantation; Bone marrow; Cord blood; Graft versus host disease; Hematopoietic stem cells; Peripheral blood

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APHERESIS; ARTHRALGIA; BONE MARROW TRANSPLANTATION; BONE PAIN; CLINICAL ARTICLE; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; REVIEW; TREATMENT OUTCOME;

ANIMALS; BONE MARROW; CELL SEPARATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 18844469943     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Thomas D. Bone marrow transplantation: past, present and future. Haematologica 1991; 76:353-6.
2. Majolino I, Aversa F, Bacigalupo A, Bandini G, Arcese W, Reali G. Allogeneic transplants of rhG-CSF-mobilized peripheral blood stem cells (PBSC) from normal donors. Haematologica 1995; 80:40-3.
3. Carlo-Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical applications. Haematologica 1995; 80:367-87.
4. Aglietta M, De Vincentiis A, Lanata L, et al. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. Haematologica 1996; 81:77-92.
5. Caligaris-Cappio F, Cavo M, De Vincentiis A, et al. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. Haematologica 1996; 81:356-75.
6. Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood 1984; 64:630-4.
7. Stroncek DF, Holland PV, Bartch G, et al. Experiences of the first 493 unrelated marrow donors in the national marrow donor program. Blood 1993; 81:1940-6.
8. Gratwohl A, Schmitz N. Introduction to First International Symposium on allogeneic peripheral blood precursor cell transplants. Bone Marrow Transplant 1996; 17(suppl 2):1-3.
9. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic transplants. Bone Marrow Transplant 1992; 9:277-84.
10. Indovina A, Majolino I, Buscerni F, et al. Engraftment kinetics and long term stability of hematopoiesis following autografting of peripheral blood progenitor cells. Haematologica 1995; 80:115-22.
11. To LB, Sheppard KM, Haylock DN, et al. Single high doses of cyclophosphamide enable the collection of high numbers of haematopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18:442-7.
12. Indovina A, Majolino I, Scimè R, et al. High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. Leuk Lymphoma 1994; 14:71-7.
13. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (rhG-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 1:640-4.
14. Gianni AM, Bregni M, Siena S, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2:580-5.
15. Auquier P, Macquart-Moulin G, Moatti JP, et al. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplany 1995; 16:541-7.
16. Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85:1659-65.
17. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85:1666-72.
18. Bensinger Wl, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995; 85:1655-8.
19. Bacigalupo A, Majolino I, Van Lint MT, et al. Transplantation of rhG-CSF mobilized allogeneic peripheral blood cells from HLA identical sibling donors [abstract]. Bone Marrow Transplant 1995; 15(suppl2):5.
20. Majolino I, Saglio G, Scimé R, et al. Hish incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17:555-60.
21. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87:1-13.
22. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993; 90:9374-8.
23. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47:1031-4.
24. Bungart B, Loeffler M, Goris H, Diehl V, Nijhof W. Differential effects of recombinant human colony stimulating factor (rh G-CSF) on stem cells in marrow, spleen and peripheral blood in mice. Br J Haematol 1990; 76:174-9.
25. Sheridan WP, Begley CG, To LB, et al. Comparison of autologous filgrastim (rhG-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14:105-11.
26. Dreger P, Haferlach T, Eckstein V, et al. rhG-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Brit J Haematol 1994; 87:609-13.
27. Majolino I, Buscemi F, Scimé R, et al. Treatment of normal donors with rhG-CSF 16 Mg/kg for mobilization of peripheral blood stem cells and their apheretic collection for allogeneic transplantation. Haematologica 1995; 80:219-26.
28. Bensinger WI, Buckner CD, Rowley S, Storb R, Appelbaum FR. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant 1996; 1(suppl 2):19-21.
29. Anderlini P, Miller P, Sundberg J, et al. "High-dose" G-CSF (filgrastim) for stem cell mobilization in normal donors: a prospective study [abstract]. Proceedings of ASCO 1996; 15:269.
30. Bensinger WI, Prince TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:1883-8.
31. Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82:1981-4.
32. Majolino I, Scimé R, Vasta S, et al. Mobilization and collection of PBSC in healthy donors. Comparison between two schemes or rhG-CSF administration. Eur J Haematol 1996; 57:214-21.
33. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitors cells in cancer patients. Blood 1988; 72:2074-81.
34. Russell JA, Luider J, Weaver M, et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15:111-5.
35. Waller CF, Bertz H, Engelhardt M, et al. Mobilization of peripheral blood progenitor cells (PBPC) for allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT): efficacy and toxicity of a high dose rhG-CSF regimen. Bone Marrow Transplant 1996; 17 (suppl 2):71.
36. Matsunaga T, Sakamaki S, Kongo Y, Ohi S, Hirayama Y, Niitsu Y. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993; 11:103-8.
37. Schwinger W, Mache C, Urban C, Beaufort F, Toglhofer W. Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers. Bone Marrow Transplant 1993; 11:489-92.
38. Bishop MR, Tarantolo SR, Schmit-Pokorny K, et al. Mobilization of blood stem cells from HLA-identical related donors with low-dose granulocyte colony-stimulating factor for allogeneic transplantation [abstract]. Blood 1995; 86(suppl 1):463.
39. Majolino I, Cavallaro AM, Bacigalupo A, et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). Haematologica 1997; 81:47-52.
40. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85:275-82.
41. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1:329-41.
42. Goldberg SL, Mangan KF, Klumpp TR, et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 1995; 4:85-90.
43. Fossa SD, Poulsen JP, Anders A. Alkaline phosphatase and lactate dehydrogenase changes during leukocytosis induced by G-CSF in testicular cancer. Lancet 1992; 340:1544.
44. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346:1432-3.
45. Hasenclever D, Sextro M. Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17(suppl 2):28-30.
46. Ohara A, Kojima S, Tsuchida M, et al. Evolution of acquired severe aplastic anemia to MDS/leukemia in childhood: a retrospective strudy on 170 severe aplastic anemia child patients. Blood 1995; 86(suppl 1):1333.
47. Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 1995; 86:4579-86.
48. Smith OP, Reeves BR, Kempski HM, Evans JP. Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol 1995; 91:150-3.
49. Ringdén O, Potter MN, Oakhill A, et al. Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplant 1996; 17(suppl 2):62-4.
50. Tjonnfjord CE, Steen R, Evensen SA, et al. Characterization of CD 34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84:2795-801.
51. Roberts AW, Metcalf D. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood 1995; 86:1600-5.
52. To LB, Haylock DN, Dowse T, et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-state PB and bone marrow CD34+ cells. Blood 1994; 84:2930-9.
53. Bregni M, Magni M, Siena S, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992; 80:1418-22.
54. Peters SO, Kittler ELW, Ramshaw HS, et al. Ex-vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11 and stem cell factor leads to impaired engraftment in irradiated host. Blood 1996; 87:30-7.
55. Lemoli RM, Tafuri A, Fortuna A, et al. Cycling status of CD 34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997; in press.
56. Pettengel R, Luft T, Henschler R, et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbelical cord blood, and blood stem cells. Blood 1994; 84:3653-9.
57. Murray L, Chen B, Galy A, et al. Enrichment of human hematopoietic stem cell activity in the CD34+ Thy-1+ Lin- subpopulation from mobilized peripheral blood. Blood 1995; 85:368-78.
58. Sutherland HJ, Eaves CJ, Lansdorp PM, Phillips GL, Hogge DH. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83:3808-14.
59. Dreger P, Klöss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86:3970-8.
60. Ponchio L, Conneally E, Eaves CJ. Quantitation of the quiescent fraction of longterm culture initianting cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood 1995; 86:3314-21.
61. Donahue RE, Kirby MR, Metzger ME, et al. Peripheral blood CD 34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor. Blood 1996; 87:1644-53.
62. Becker PS, Li Z, Quesenberry PJ. Cytokine regulation of cell adhesion receptor expression in hematopoietic cells. Blood 1994; 84:280a (abstr. Suppl. 1).
63. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL. Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc Natl Acad Sci USA 1993; 90:3760-4.
64. Kovach NL, Lin N, Yednock T, Harlan JM, Broudy VC. Stem cell factor modulates avidity of α4β1 and α5β1 integrins expressed on hematopoietic cell lines. Blood 1995; 85:159-67.
65. Möhle R, Murea S, Kirsch M, Haas R. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood durin G-CSF-enhanced recovery. Ex Hematol 1995; 23:1535-42.
66. Gabutti V, Foà R, Mussa F, Aglietta M. Behavior of human hematopoietic stem cells in cord and neonatal blood. Haematologica 1975; 60:492.
67. Broxmeyer HE, Douglas GW, Hancgoc G, et al. Human umbilical cord as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA, 1989; 86:3828.
68. Gluckman E, Broxmeyer HE, Auerbach DA, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989; 321:1174-8.
69. Bertolinl F, Lazzari L, Lauri L, et al. A comparative study of different procedures for the collection and banking of umbilical cord blood. J Hematother 1995; 4:29-36.
70. Bertolini F, Soligo D, Lazzari L, Corsini C, Servida F, Sirchia G. The effect of interkleukin 12 in ex-vivo expansion of human hematopoietic progenitors. Br J Haematol 1995; 90:935-8.
71. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three loci" incompatible transplants in leukemia patients by addition of recombinant human G-CSF-mobilized peripheral blood progenitor cells to bone marrow inocolum. Blood 1994; 84:3948-55.
72. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346:214-9.
73. Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993; 178:787-91.
74. Hows JM, Bradley BA, Marsh JCW, et al. Growth of human umbilical-cord blood in longterm haemopoietic cultures. Lancet 1992; 340:73-6.
75. Payne TA, Traycoff CM, Laver J, Xu F, Srour EF, Abboud MR. Phenotypic analysis of early hematopoietic progenitors in cord blood and determination of their correlation with clonogenic progenitors: relevance to cord blood stem cell transplantation. Bone Marrow Transplant 1995; 15:187-92.
76. Traycoff CM, Abboud MR, Laver J, et al. Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp Hematol 1994; 22:215-22.
77. Gabutti V, Timeus F, Ramenghi U, et al. Expansion of cord blood progenitors and use for hemopoietic reconstitution. Stem Cells 1993; 11(Suppl. 2):105-12.
78. Moritz T, Keller DC, Williams DA. Human cord blood cells as targets for gene transfer. Potential use in genetic therapies of SCID. J Exp Med 1993; 178:529-36.
79. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med 1995; 1:1017-23.
80. Bertolini F, De Monte L, Corsini C, et al. Retrovirus-mediated transfer of the multidrug resistance gene into human haematopoietic progenitors. Br J Haematol 1994; 88:318-24.
81. Bertolini F, Battaglia M, Corsini C, et al. Engineered stromal layers and continuous flow culture enhance multidrug resistance gene transfer in hematopoietic progenitors. Cancer Res 1996; 56:2566-72.
82. Traycoff CM, Abboud MR, Laver J, Clapp DW, Srour EF. Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential. Exp Hematol 1994; 22:1264-72.
83. Lambertenghi-Deliliers G, Bertolini F, Della Volpe A, et al. Unrelated mismatched cord blood transplantation in an adult patient with secondary AML Bone Marrow Transplant 1997; in press .
84. Traycoff CM, Cornetta K, Yoder MC, et al. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential. Exp Hematol 1996; 24:229-306.
85. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 7:1679-90.
86. Kögler G, Somville Th, Adams O, et al. Critical standards for stem cell preparations from unrelated cord blood within Eurocord. Exp Hematol 1995; 22:898.
87. Gluckman E, Devergie A, Thierry D, et al. Clinical application of stem cells transfusion from cord blood and rationale for cord blood banking. Bone Marrow Transplant 1992; 9 Suppl 1:114-7.
88. Turner CW, Luzins J, Hutcheson CA. A modified harvest technique for cord blood hematopoietic stem cells. Bone Marrow Transplant 1992; 10:89.
89. Abecasis MM, Machado AM, Boavida G, et al. Haploidentical cord blood transplant contaminated with maternal T cells in a patient with advanced leukemia. Bone Marrow Transplant 1996; 17:891-5.
90. Yao AC, Moinian M, Lind J. Distribution of blood between infant and placenta after birth. Lancet 1969; 2:871.
91. Yao AC, Lind J. Effect of gravity on placental transfusion. Lancet 1969; 2:508.
92. Nelle M, Zilow EP, Kraus M, Bastert G, Linderkamp O. The effect of the Leboyer delivery on blood viscosity and other hemorheologic parameters in term neonates. Am J Ob Gyn 1993; 169:189-93.
93. Sinclair JC, Bracken MB. eds. Effective care of newborn infant. Oxford: Oxford Medical Publications; 1992.
94. Roberton NRC, ed. Textbook of neonatology. London: Churchill Livingstone; 1992.
95. Pritchard JA, McDonald PC, Grant NF, eds. William's Obstetrics. Norwalk: Appelton-Century-Crofts; 1985.
96. Taeush HW, Ballard RA, Avery ME. eds. Schaffer and Avert's diseases of the newborn. Philadelphia :WB Saunders; 1991.
97. Polin RA, Fox WW, eds. Fetal and neonatal physiology. Philadelphia: WB Saunders; 1992.
98. Bertolini F, Battaglia M, De lulio C, et al. Placental blood collection: Effects on newborns. Blood 1995; 86:4699.
99. Harris DT, Schumacher MJ, Rychlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant 1994; 13:135-43.
100. Almici C, Carlo-Stella C, Mangoni L, et al. Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: Implications for cord blood banking. Stem Cells 1995; 13:533-40.
101. Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92:10119-22.
102. Bertolini F, Baccaglia M, Zibera C, et al. A new method for placental/cord processing in the collection bag. Analysis of factors involved in red blood cell removal. Bone Marrow Transplant 1996; in press.
103. Pahwa RN, Fleischer A, Than S, Good RA. Successful hematopoietic reconstitution with transplantation of erythrocyte-depleted allogeneic human umbilical cord blood cells in a child with leukemia. Proc Natl Acad Sci USA 1994; 91:4485-8.
104. Di Giusto DL, Lee R, Moon J, et al. Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 1996; 87:1261-71.
105. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive hemetopoietic cells (long-term culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 1996; 93:1470-4.
106. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995; 333:283-7.
107. Williams SF, Lee WL, Bender JG, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87:1687-91.
108. Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402-13.
109. Okamoto Y, Takaue Y, Saito S, et al. Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer. Transfusion 1993; 33:578-81.
110. Burgio GR, Hanson LA, Ugazio AG, eds. Immunology of the neonate. Berlin: Springer-Verlag; 1987. p. 188.
111. Jacoby DR, Olding LB, Oldstone MBA. Immunologic regulation of fetal-maternal balance. Adv Immunol 1984; 35:157-208.
112. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Buck D, Terstappen LWMM. Control of lymphocyte recirculation in man. J Immunol 1993; 150:1105-21.
113. Clement LT, Vink PE, Bradley GE. Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate. J Immunol 1990; 145:102-8.
114. Burgio GR, Curtoni E, Genova R, Magrini U. Skin reactivity in childhood: phytohemagglutinin skin test and streptokinase skin test. Ped Res 1971; 5:88-93.
115. Clerici M, De Palma L, Roilides E, Baker R, Shearer GM. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest 1993; 91:2829-36.
116. Maccario R, Nespoli L, Vitiello A, Ugazio AG, Burgio GR. Lymphocyte subpopulations in the neonate: identification of an immature subset of OKT8-positive, OKT3-negative cells. J Immunol 1983; 130:1129-31.
117. Harris DT, Schumacher MJ, Locascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA 1992; 89:10006-10.
118. Moller G. Ontogeny of human lymphocyte function. Immunol Rev 1981; 57:161.
119. Keever CA, Abu-Hajir M, Graf W, et al. Characterization of alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 1995; 15:407-19.
120. Brugnoni D, Airo P, Graf D, et al. Ineffective expression of CD40 ligand on cord blood T cells may contribute to poor immunoglobulin production in the newborn. Eur J Immunol 1994; 24:1919-24.
121. Montagna D, Maccario R, Ugazio AG, Mingrat G, Burgio GR. Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity. Clin Exp Immunol 1988; 71:158-65.
122. Moretta A, Comoli P, Montagna D, et al. High frequency of EBV-lymphoblastoid cell line-reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL-2 production. Clin Exp Immunol 1996; in press.
123. Moller G. Immunology of feto-maternal relationship. Immunol Rev 1983; 75:175.
124. Claas FHJ, Gijbels Y, van der Velden-de Munck J, van Rood JJ. Induction of B cell unresponsiveness to noninherited maternal antigens during fetal life. Science 1988; 241:1815-7.
125. Zhang L, van Bree S, van Rood JJ, Claas FHJ. The influence of breastfeeding on the T cell allorepertoire. Transplantation 1991; 52:914-6.
126. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346:214-9.
127. Burnet FM. The clonal selection theory of acquired immunity. Nashville: Vanderbilt Univ. Press; 1959.
128. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996; 271:1723-6.
129. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 1996; 271:1726-8.
130. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science 1996; 271:1728.
131. Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human umbilical cord blood T lymphocytes following allogeneic stimulation. Cell Immunol 1994; 154:14-24.
132. Harris DT, Schumacher MJ, LoCascio J, Booth A, Bard J, Boyse EA. Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation. Bone Marrow Transplant 1994; 14:63-8.
133. Harris DT, LoCascio J, Besencon FJ. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. Bone Marrow Transplant 1994; 14:545-53.
134. Deacock SJ, Schwarer AP, Bridge J, Batchelor JR, Goldman JM, Lechler RI. Evidence that umbilical cord blood contains a higher frequency of HLA class II-specific alloreactive T cells than adult peripheral blood. Transplantation 1992; 53:1128-34.
135. Apperley JF. Umbilical cord blood progenitor cell transplantation. Bone Marrow Transplant 1994; 14:187-96.
136. Risdon G, Gaddy J, Horie M, Broxmeyer HE. Alloantigen priming induces a state of unresponsiveness in human umbilicalcord blood T cells. Proc Natl Acad Sci USA 1995; 92:2413-7.
137. Harris DT. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 1995; 15:17-23.
138. Butturini A, Franceschini F, Gale RP. Critical analysis of T-cell depletion in man. In: Martelli MF, Grignani F, Reisner Y, eds. T-cell depletion in allogeneic bone marrow transplantation. Rome: Serono Symposia Review; 1988. p. 1-13.
139. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667-74.
140. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, Dr incompatible parental marrow fractioned by soybean aggluunin and sheep red blood cells. Blood 1983; 61:341-8.
141. O' Reilly RJ, Kernan N, Cunningham I, et al. Soybean lectin agglutination and E-rosette depletion for removal of T-cells from HLA-identical and non-identical marrow grafts administered for the treatment of leukemia. In: Martelli MF, Grignani F, Reisner Y, eds. T cell depletion in allogeneic bone marrow transplantation. Rome: Serono Symposia Review; 1988. p. 123-9.
142. Ash RC, Casper JT, Chitamba CR, et al. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322:485-94.
143. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83:1980-7.
144. Kernan NA, Flomenberg N, Dupont B, et al. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Transplantation 1987; 43:842-7.
145. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T cell depletion. Ann Intern Med 1988; 108:806-14.
146. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-62.
147. O'Reilly R. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol 1992; 29(Suppl. 1):20-6.
148. Kessinger A, Smith DM, Strandjord SE, et al. Allogeneic transplantation of blood derived, T-cells depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4:643-6.
149. Suzue T, Kawano Y, Takaue Y, et al. Cell processing protocol for allogeneic peripheral blood stem cells mobilized by granulocyte colony-stimulating factor. Exp Hematol 1994; 22:888-92.
150. Keij JF, Groenewegen AC, Visser JWM. High-speed photodamage cell sorting: an evaluation of the ZAPPER prototype. In: Darzynkiewicz Z, Robinson JP, Crissman HA, eds. Methods in cell biology. New York: Academic Press; 1994. p. 371-85.
151. Link H, Arseniev L, Bahre O, et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 1995; 86:2500-8.
152. Arseniev L, Tischler HJ, Battmer K, et al. Treatment of poor graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplant 1994; 14:791-7.
153. Di Persio J, Martin B, Abbond C, et al. Allogeneic BMT using bone marrow and CD34-selected mobilized PBSC; comparison to BM alone and mobilized PBSC alone. Exp Hematol 1994; 22:697a.
154. Lemoli RM, Tazzari PL, Fortuna A, et al. Positive selection of hematopoietic CD34+ stem cells provides "indirect purging" of CD34- lymphoid cells and the purging efficiency is increased by anti CD2 and anti-CD30 immunotoxins. Bone Marrow Transplant 1994; 13:465-71.
155. Behringer D, Bertz H, Hardung-Backes M, et al. Allogeneic peripheral blood progenitor cell transplantation with or without CD34+ stem cell selection: follow up and immune reconstitution. Bone Marrow Transplant 1996; 17 (Suppl. 1):298a.
156. Keman NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vs-host disease. Blood 1986; 68:770-3.
157. Aversa F, Terenzi A, Tabilio A, et al. Addition of PBSCs to the bone marrow inoculum allows engraftment of T-cell-depleted HLA-incompatible transplants. Br J Haematol 1996; 93 (Suppl. 2):146.
158. Tabilio A, Falzetti F, Aversa F, et al. T cell depletion of peripheral blood stem cells by CD34+ cell selection and E-rosettes. Submitted for publication.
159. Fernandez JM, Yan Y, Bleans S, et al. T-cell depletion of peripheral blood progenitor cells (PBPC) by either CD34+ selection and E-rosette depletion or SBA agglutination and E-rosette depletion: comparison of T-cell and hematopoietic cell progenitor recovery. Blood 1995; 86 (Suppl. 1):626a.
160. Slaper-Cortenbach ICW, Wijngaarden-du Bois MJGJ, de Vriesvan Rossen A, et al. New immunorosette technique for the depletion of T cells from allogeneic stem cell transplantation. Br J Haematol 1996; 93(Suppl. 2):170a.
161. rd, 1996.
162. Kunkel L, Mills B, Burgess J, et al. Early experiences with selection of CD34+ cells and peptide release using a fully automated selection process. In: Latest advancements in immunomagnetic Cell selection for grafts engineering in autologous and allogeneic stem cell transplantation. EBMT Baxter satellite symposium. Vienna, March 3rd, 1996.
163. Berenson RJ, Bensinger WI, Hill RS, etal. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77:1717-22.
164. Gorin NC, Lopez M, Laporte JP, et al. Preparation and succesful engraftment of purified CD34+ bone marrow progenitor cells in patients with non Hodgkin's lymphorna. Blood 1995; 85:1647-54.
165. Lemoli RM , Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87:1625-34.
166. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96.
167. Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180:1841-7.
168. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating Factor plus Interleukin 4 and downregulated by tumor necrosis factor. J Exp Med 1994; 179:1109-18.
169. Romani R, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
170. Hart DN, Starling GC, Calder VL, Fernando NS. B7/BB-1 is a leukocyte differentiation antigen on human dendritic cells induced by activation. Immunology 1993; 79:616-20.
171. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84:3261-82.
172. Reid CDL, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149:2681-8.
173. Szalbocs P, Moore MAS, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, GM-CSF and TNF-α. J Immunol 1995; 154:5851-61.
174. Young JW, Szalbocs P, Moore MAS. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit ligand and yeld pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor-α. J Exp Med 1995; 182:1111-20.
175. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995; 23:1463-71.
176. Rosenzwaig M, Canque B, Gluckman JC. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 1996; 87:535-44.
177. Strunk D, Rappesberger K, Egger C, et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87:1292-302.
178. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 48:1349-56.
179. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177:165-73.
180. DeSilva DS, Urdhal KB, Jenkins MK. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991; 147:2461-6.
181. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1:443-6.
182. Rondelli D, Andrews RG, Hansen JA, Ryncarz R, Faerber MA, Anasetti C. Alloantigen presenting function of normal human CD34+ hematopoietic cells. Blood 1996; 88:2619-25.
183. Gunji Y, Nakamura M, Yanigisawa M, Miura Y, Suda T. Expression and function of adhesion molecules on human hematopoietic stem cells: CD34+LFA-1- cells are more primitive than CD34+LFA-1+ cells. Blood 1992; 80:429-36.
184. Krensky AM, Mentzer SJ, Clayberger C, et al. Heritable lymphocyte function-associated antigen-1 deficiency: abnormalities of cytotoxicity and proliferation associated with abnormal expression of LFA-1. J Immunol 1985; 135:3102-8.
185. Andrews RG, Bryant EM, Bartelmez SH, et al. CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. Blood 1992; 80:1693-701.
186. Bensinger WI, Rowley S, Appelbaum FR, et al. CD34 selected allogeneic peripheral blood stem cell (PBSC) transplantation in older patients with advanced hematologic malignancies. Blood 1995; 86 (Suppl.1):376.
187. Schiller C, Rowley S, Buckner CD, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in older patients with advanced hematologic malignancy. Blood 1995; 86 (Suppl.1):1545.
188. Link H, Arseniev L, Bahre O, et al. Transplantation or allogeneic hematopoiesis by selected CD34+ blood cells. Blood 1995; 86 (Suppl.1):1150.
189. Urbano-Ispizua A, Rozman C, Marìn P, et al. Selection of CD34+ peripheral blood progenitor cells (PBPC) for allogeneic transplantation. Blood 1995; 86(Suppl.1):901.
190. Holland HK, Bray AM, Geller RB, et al. Transplantation of HLA-identical positively selected CD34+ cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation. Blood 1995; 86(Suppl.1):1543.
191. Weaver CH, Longin K, Buckner CD, et al. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13:411-5.
192. Nicola NA. Why do hemopoietic growth factor receptors interact with each other? Immunol Today 1987; 8:134-40.
193. Noga SJ, Davis JM, Vogelsgang GB, et al. The combined use of elutriation and CDS/magnetic bead to engineer the bone marrow allograft. In: Worthington-White DA, Gee AP, Gross S, eds. Advances in bone marrow purging and processing. New York: Wiley-Liss; 1992. p. 411.
194. Owens AH, Santos GW. The induction of graft versus host disease in mice created with cyclophosphamide.J Exp Med 1968; 128:277-91.
195. van Bekkum DW, de Vries MJ. Radiation chimaeras. New York: Academic Press; 1967.
196. Atkinson K, Farrell C, Chapman G, et al. Female marrow donors increase the risk of acute graft-versus-host-disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63:231-9.
197. Jansen J, Goselink HM, Veenhof WFJ, et al. The impact of the composition of the bone marrow graft on engraftment and graft-versus-host-disease. Exp Hematol 1983; 11:967-73.
198. Murphy WJ, Reynolds CW, Tiberghien P, Longo DL. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst 1993; 85:1475-82.
199. Zeis M, Uharek L, Glass B, et al. Natural killer cells given after allogeneic BMT induce strong graft-vs-leukemia (GVL) effects. Br J Haematol 1996; 93 (suppl 2):76a.
200. van Bekkum DW. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. Effect of storage at 4°C. Transplantation 1964; 2:393-8.
201. Eckardt JR, Roodman GD, Boldt DH, et al. Comparison of engraftment and acute GvHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant 1993; 11:125-31.
202. Dreger P, Suttorp M, Haferlach T, et al. Allogeneic granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells for treatment of engraftmem failure after bone marrow transplantation. Blood 1993; 81:1404-7.
203. Rambaldi A, Viero P, Bassan R, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute teukemias. Leukemia 1996; 10:860-5 .
204. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335:157-66.
205. Laporte JP, Gorin NC, Rubinstein P, et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1996; 335:167-70.